Heart boost can improve outcome for sickest heart attack patients

November 13, 2000

NEW ORLEANS - Based on the results of a small clinical trial, Duke University Medical Center researchers have found that artificially intensifying the heart's pumping action can improve the outcome of heart attack patients who have gone into shock, a condition that is responsible for 60 percent of heart attack deaths in hospital.

This technique, called aortic counterpulsation, is achieved by means an intra-aortic balloon pump (IABP), and when used in conjunction with clot-busting drugs, showed modest but significant benefits for the sickest heart attack patients, according to the Duke researchers.

"IABP technology has been around for more than 20 years, and it is definitely an underutilized procedure," said Dr. Magnus Ohman, cardiologist at the Duke Clinical Research Institute (DCRI). "This procedure can help many of these extremely ill patients without additional risks."

Ohman prepared the results of his study for presentation Tuesday at the 73rd annual scientific sessions of the American Heart Association. The study was funded by Datascope Corp., Montvale, N.J.

Shock is a potentially life-threatening condition that occurs when blood pressure becomes too low to sustain normal bodily functions. While shock has many different causes, in heart attack patients it occurs when the heart is starved of its supply of oxygen-rich blood and is therefore unable to pump enough blood throughout the body.

Typically, when acute heart attack patients come to an emergency room, initial treatment is with so-called clot-busting drugs - also known as thrombolytics - which dissolve blood clots in coronary arteries and restore normal blood flow to the heart muscle.

IABP is simply a long balloon that is threaded from an insertion point in the groin through the heart and into the aorta. The balloon is then inflated and deflated in conjunction with the contraction and relaxation rhythms of the heart, intensifying its pumping action.

The researchers wanted to know if adding IABP to the standard thrombolytic therapy would improve outcomes for this difficult-to-treat patient population.

Thus was born the Thrombolytic And Counterpulsation To Improve Cardiogenic shock Survival (TACTICS) trial, which prospectively enrolled 57 patients from 1996-1999 at 17 hospitals in the United States, Australia and Europe. Patients were randomized to either thrombolytic therapy alone or thrombolytic therapy followed by IABP.

"The six-month mortality rate for patients with the combined therapy was 39 percent, compared to 43 percent for thrombolytic therapy alone," Ohman said. "While the difference appears small, the patients receiving the combined therapy tended to be much sicker, and those with the most to gain.

"We routinely use IABP at Duke for these types of very ill patients, and recommend that community hospitals do the same," Ohman said.

The combined therapy patients tended to be older (68 vs. 67), have more diabetes (30 percent vs. 11 percent), have had previous heart attacks (40 percent vs. 19 percent), and have more severe heart disease (60 percent vs. 48 percent).

The original design of the trial called for an assessment of the therapies after the first 100 patients; however, the trial was halted after 57 patients had been enrolled and treated.

"Since these are the very sickest of heart attack patients, it was very difficult to enroll enough patients," Ohman continued. "But based on the safety data, and the positive results from the patients who did receive IABP, we believe that this is an effective approach for acute heart patients who go into shock."

Patients remained on the IABP for more than three days on average.
-end-
Joining Ohman in the study were Dr. John Nannas, Alexandra Hospital, Athens, Greece; Dr. Robert J. Stomel, Botsford General Hospital, Farmington Hill, Mich.; Dr. Massoud A. Leesar, University of Louisville Hospital, Louisville, KY.; Dr. Dennis Nielsen, Central Hospital in Rogaland, Bergen, Norway; Dr. Michael P. Hudson, DCRI; Beth Fraulo, DCRI; Linda K. Shaw, DCRI; Kerry L. Lee, Duke; Dr. Daniel O'Dea, Hudson Valley Heart Center, Poughkeepsie, N.Y.; Dr. Felix J. Rogers, Riverside Osteopathic Hospital, Trenton, Mich.; and Dr. Daniel Harber, Garden City Hospital, Garden City, Mich.

Duke University Medical Center

Related Heart Articles from Brightsurf:

New 'atlas' of human heart cells first step toward precision treatments for heart disease
Scientists have for the first time documented all of the different cell types and genes expressed in the healthy human heart, in research published in the journal Nature.

Highly detailed map of the human heart could guide personalized heart treatments
Scientists have created a detailed cellular and molecular map of the healthy human heart to understand how this vital organ functions and to shed light on what goes awry in cardiovascular disease.

Highly detailed map of human heart could guide personalised heart treatments
Scientists have created the most detailed cellular and molecular map of the healthy human heart ever, to understand how the heart functions, and illuminate what goes wrong in cardiovascular disease.

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Molecular imaging identifies link between heart and kidney inflammation after heart attack
Whole body positron emission tomography (PET) has, for the first time, illustrated the existence of inter-organ communication between the heart and kidneys via the immune system following acute myocardial infarction.

New heart valve could transform open heart surgery for millions of patients globally
A new polymeric heart valve with a life span potentially longer than current artificial valves that would also prevent the need for the millions of patients with diseased heart valves to require life-long blood thinning tablets has been developed by scientists at the universities of Bristol and Cambridge.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Digital heart model will help predict future heart health, new study finds
In recent times, researchers have increasing found that the power of computers and artificial intelligence is enabling more accurate diagnosis of a patient's current heart health and can provide an accurate projection of future heart health, potential treatments and disease prevention.

Read More: Heart News and Heart Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.